Managing Remnant Cholesterol: Fenofibrate-Statin Therapy Evidence Summary

A growing body of evidence suggests remnant cholesterol contributes to residual cardiovascular risk even after LDL-C control. This table summarizes clinical and real-world evidence on the efficacy and safety of fenofibrate-statin combination therapy for reducing triglyceride-rich lipoproteins. The dataset, authored by Vikrama Raja and shared under a CC-BY-4.0 license, was last updated on June 4, 2026.

Use Cases

• Analyze the role of remnant cholesterol in residual cardiovascular risk based on the description of its contribution to major adverse cardiovascular events.
• Evaluate the efficacy of fenofibrate-statin combination therapy based on evidence from clinical trials and real-world studies mentioned in the description.
• Assess the long-term safety and tolerability of fenofibrate based on the description of studies spanning up to two decades.

Strengths

• The description references evidence from clinical trials and real-world studies, suggesting a multi-source evidence base.
• The dataset is licensed under CC-BY-4.0, allowing for broad reuse and sharing.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 12.2 KB, indicating limited scope.

Provenance

Source

figshare

Freshness

Last updated 2026-06-04 04:27:22; freshness should be verified.